Diagnosis and management of neurogenic orthostatic hypotension

키워드

참고문헌 (91)

1. Robertson D, "The pathophysiology and diagnosis of orthostatic hypotension", Clin Auton Res, 18, pp.2~7 (2008)
2. Shibao C, "Evaluation and treatment of orthostatic hypotension", J Am Soc Hypertens, 7, pp.317~324 (2013)
3. Wieling W, "Diagnosis and treatment of orthostatic hypotension", Lancet Neurol, 21, pp.735~746 (2022)
4. Low PA, "Management of neurogenic orthostatic hypotension : an update", Lancet Neurol, 7, pp.451~458 (2008)
5. Lanfranchi PA, "Arterial baroreflex function and cardiovascular variability : interactions and implications", Am J Physiol Regul Integr Comp Physiol, 283, pp.R815~R826 (2002)
6. Magkas N, "Orthostatic hypotension : from pathophysiology to clinical applications and therapeutic considerations", J Clin Hypertens(Greenwich), 21, pp.546~554 (2019)
7. Kanjwal K, "Orthostatic hypotension : definition, diagnosis and management", J Cardiovasc Med(Hagerstown), 16, pp.75~81 (2015)
8. Freeman R, "Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome", Clin Auton Res, 21, pp.69~72 (2011)
9. Gibbons CH, "The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension", J Neurol, 264, pp.1567~1582 (2017)
10. Freeman R, "Orthostatic hypotension : JACC state-of-the-art review", J Am Coll Cardiol, 72, pp.1294~1309 (2018)
11. Tzur I, "Delayed versus classic orthostatic hypotension : clinical and prognostic implications", Blood Press, 29, pp.209~219 (2020)
12. Brignole M, "Practical instructions for the 2018 ESC guidelines for the diagnosis and management of syncope", Eur Heart J, 39, pp.e43~ (2018)[DOI]
13. Gibbons CH, "Clinical implications of delayed orthostatic hypotension : a 10-year follow-up study", Neurology, 85, pp.1362~1367 (2015)
14. Byun JI, "Delayed orthostatic hypotension : severity of clinical symptoms and response to medical treatment", Auton Neurosci, 213, pp.81~85 (2018)
15. van Wijnen VK, "Initial orthostatic hypotension in teenagers and young adults", Clin Auton Res, 26, pp.441~449 (2016)
16. Wieling W, "Initial orthostatic hypotension : review of a forgotten condition", Clin Sci(Lond), 112, pp.157~165 (2007)
17. Vinik AI, "Diabetic cardiovascular autonomic neuropathy", Circulation, 115, pp.387~397 (2007)
18. Finucane C, "Impaired orthostatic blood pressure recovery is associated with unexplained and injurious falls", J Am Geriatr Soc, 65, pp.474~482 (2017)
19. Doyle K, "Delayed blood pressure recovery after standing independently predicts fracture in community-dwelling older people", J Am Med Dir Assoc, 22, pp.1235~1241 (2021)
20. Mol A, "Orthostatic blood pressure recovery associates with physical performance, frailty and number of falls in geriatric outpatients", J Hypertens, 39, pp.101~106 (2021)
21. van Twist DJL, "Delayed recovery from initial orthostatic hypotension : an expression of frailty in the elderly", Clin Auton Res, 30, pp.105~106 (2020)
22. Centi J, "Effects of orthostatic hypotension on cognition in Parkinson disease", Neurology, 88, pp.17~24 (2017)
23. Robertson D, "The head and neck discomfort of autonomic failure : an unrecognized aetiology of headache", Clin Auton Res, 4, pp.99~103 (1994)
24. Bleasdale-Barr KM, "Neck and other muscle pains in autonomic failure : their association with orthostatic hypotension", J R Soc Med, 91, pp.355~359 (1998)
25. Gibbons CH, "Orthostatic dyspnea : a neglected symptom of orthostatic hypotension", Clin Auton Res, 15, pp.40~44 (2005)
26. Palma JA, "Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?", Mov Disord, 30, pp.639~645 (2015)
27. Freeman R, "Symptom recognition is impaired in patients with orthostatic hypotension", Hypertension, 75, pp.1325~1332 (2020)
28. Arbogast SD, "Hypotension unawareness in profound orthostatic hypotension", Am J Med, 122, pp.574~580 (2009)
29. Shaw BH, "Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a ‘sit-to-stand test’", J Hypertens, 35, pp.1019~1025 (2017)
30. Cremer A, "Screening for orthostatic hypotension using home blood pressure measurements", J Hypertens, 37, pp.923~927 (2019)
31. Gibbon JR, "Feasibility, reliability and safety of self-assessed orthostatic blood pressure at home", Age Ageing, 51, pp.afac153~ (2022)
32. Norcliffe-Kaufmann L, "Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies", Ann Neurol, 83, pp.522~531 (2018)
33. Lamotte G, "Updates on the diagnosis and treatment of peripheral autonomic neuropathies", Curr Neurol Neurosci Rep, 22, pp.823~837 (2022)
34. Freeman R, "Autonomic peripheral neuropathy", Neurol Clin, 25, pp.277~301 (2007)
35. Zaeem Z, "Autonomic involvement in Guillain-Barré syndrome : an update", Clin Auton Res, 29, pp.289~299 (2019)
36. Palma JA, "Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management", Clin Auton Res, 29, pp.33~44 (2019)
37. Goldstein DS, "Neurogenic orthostatic hypotension : a pathophysiological approach", Circulation, 119, pp.139~146 (2009)
38. Mendoza-Velásquez JJ, "Autonomic dysfunction in α-synucleinopathies", Front Neurol, 10, pp.363~ (2019)
39. Harms MP, "Continuous stroke volume monitoring by modelling flow from non-invasive measurement of arterial pressure in humans under orthostatic stress", Clin Sci(Lond), 97, pp.291~301 (1999)
40. Idiaquez JF, "Neurogenic orthostatic hypotension. Lessons from synucleinopathies", Am J Hypertens, 34, pp.125~133 (2021)
41. Smit AA, "Pathophysiological basis of orthostatic hypotension in autonomic failure", J Physiol, 519, pp.1~10 (1999)
42. Benarroch EE., "The central autonomic network: functional organization, dysfunction, and perspective", Mayo Clin Proc, 68, pp.988~1001 (1993)
43. Cryer PE, "Reduced plasma norepinephrine response to standing in autonomic dysfunction", Arch Neurol, 33, pp.275~277 (1976)
44. Mantovani G, "Supine hypertension : a state of the art", Auton Neurosci, 241, pp.102988~ (2022)
45. Fanciulli A, "Supine hypertension in Parkinson’s disease and multiple system atrophy", Clin Auton Res, 26, pp.97~105 (2016)
46. Jordan J, "What do we really know about supine hypertension in patients with orthostatic hypotension", Curr Opin Cardiol, 34, pp.384~389 (2019)
47. Fanciulli A, "Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society(AAS)and the European Federation of Autonomic Societies(EFAS) : endorsed by the European Academy of Neurology(EAN)and the European Society of Hypertension(ESH)", Clin Auton Res, 28, pp.355~362 (2018)
48. Jordan J, "Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension", J Hypertens, 37, pp.1541~1546 (2019)
49. Biaggioni I, "Primer on the autonomic nervous system", pp.699~704 (2023), Elsevier
50. Ando Y, "Autonomic dysfunction and anemia in neurologic disorders", J Auton Nerv Syst, 61, pp.145~148 (1996)
51. Bolek H, "Orthostatic hypotension among elderly patients in Italian internal medicine wards : an observational study-comment", Intern Emerg Med, 15, pp.1353~1354 (2020)
52. Wieling W, "Physical countermeasures to increase orthostatic tolerance", J Intern Med, 277, pp.69~82 (2015)
53. Palma JA, "Management of orthostatic hypotension", Continuum(Minneap Minn), 26, pp.154~177 (2020)
54. van Dijk N, "Hemodynamic effects of leg crossing and skeletal muscle tensing during free standing in patients with vasovagal syncope", J Appl Physiol(1985), 98, pp.584~590 (2005)
55. Krediet CT, "Leg crossing, muscle tensing, squatting, and the crash position are effective against vasovagal reactions solely through increases in cardiac output", J Appl Physiol(1985), 99, pp.1697~1703 (2005)
56. Wilcox CS, "Sodium homeostasis in patients with autonomic failure", Clin Sci Mol Med, 53, pp.321~328 (1977)
57. Williams EL, "Salt supplementation in the management of orthostatic intolerance : vasovagal syncope and postural orthostatic tachycardia syndrome", Auton Neurosci, 237, pp.102906~ (2022)
58. Stock JM, "Dietary sodium and health: how much is too much for those with orthostatic disorders?", Auton Neurosci, 238, pp.102947~ (2022)
59. Mtinangi BL, "Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope", Clin Auton Res, 8, pp.231~235 (1998)
60. Snapper H, "Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome", Auton Neurosci, 238, pp.102951~ (2022)
61. Jordan J, "The pressor response to water drinking in humans : a sympathetic reflex?", Circulation, 101, pp.504~509 (2000)
62. Lipp A, "Osmosensitive mechanisms contribute to the water drinking-induced pressor response in humans", Neurology, 65, pp.905~907 (2005)
63. McHugh J, "Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control", Hypertension, 55, pp.1438~1443 (2010)
64. May M, "The osmopressor response to water drinking", Am J Physiol Regul Integr Comp Physiol, 300, pp.R40~R46 (2011)
65. Podoleanu C, "Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons : a randomized single-blind controlled study", J Am Coll Cardiol, 48, pp.1425~1432 (2006)
66. Ricci F, "Orthostatic hypotension:epidemiology, prognosis, and treatment", J Am Coll Cardiol, 66, pp.848~860 (2015)
67. Bourne KM, "Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome", J Am Coll Cardiol, 77, pp.285~296 (2021)
68. Lahrmann H, "EFNS guidelines on the diagnosis and management of orthostatic hypotension", Eur J Neurol, 13, pp.930~936 (2006)
69. Figueroa JJ, "Preventing and treating orthostatic hypotension: as easy as A, B, C", Cleve Clin J Med, 77, pp.298~306 (2010)
70. Shibao C, "ASH position paper : evaluation and treatment of orthostatic hypotension", J Clin Hypertens(Greenwich), 15, pp.147~153 (2013)
71. Wright RA, "A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension", Neurology, 51, pp.120~124 (1998)
72. Jankovic J, "Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine", Am J Med, 95, pp.38~48 (1993)
73. Low PA, "Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study", JAMA, 277, pp.1046~1051 (1997)
74. Smith W, "Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension:a phase 4, double-blind, placebo-controlled, randomized, tilt-table study", Clin Auton Res, 26, pp.269~277 (2016)
75. Ten Harkel AD, "Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone", J Intern Med, 232, pp.139~145 (1992)
76. Pavy-Le Traon A, "Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy", Eur J Neurol, 29, pp.1025~1034 (2022)
77. Grijalva CG, "Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension", J Am Heart Assoc, 6, pp.e006848~ (2017)
78. Palma JA, "Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension", Neurology, 91, pp.e1539~e1544 (2018)
79. Biaggioni I, "Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa", Hypertension, 65, pp.101~107 (2015)
80. Kaufmann H, "Droxidopa for neurogenic orthostatic hypotension:a randomized, placebo-controlled, phase 3 trial", Neurology, 83, pp.328~335 (2014)
81. Hauser RA, "Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease(nOH306B)", Mov Disord, 30, pp.646~654 (2015)
82. Hauser RA, "Durability of the clinical benefit of droxidopa for neurogenic orthostatic hypotension during 12 weeks of open-label treatment", Neurol Ther, 11, pp.459~469 (2022)
83. Owen R, "Rationale and design of the neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy (RESTORE) study (P5. 131)", Neurology, 86, pp.131~ (2016)
84. Shibao CA, "Predictors of the pressor response to the norepinephrine transporter inhibitor, atomoxetine, in neurogenic orthostatic hypotension", Hypertension, 78, pp.525~531 (2021)
85. Ramirez CE, "Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure", Hypertension, 64, pp.1235~1240 (2014)
86. Kaufmann H, "Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension : a phase 2trial", Clin Auton Res, 31, pp.699~711 (2021)
87. Palma JA, "Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension", Mov Disord Clin Pract, 4, pp.298~308 (2017)
88. Lamotte G, "Orthostatic hypotension in parkinson disease : what is new?", Neurol Clin Pract, 12, pp.e112~e115 (2022)
89. Singer W, "Pyridostigmine treatment trial in neurogenic orthostatic hypotension", Arch Neurol, 63, pp.513~518 (2006)
90. Schreglmann SR, "Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease-a randomized controlled trial", Eur J Neurol, 24, pp.545~551 (2017)
91. Okamoto LE, "Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension", Hypertension, 73, pp.235~241 (2019)

관련 논문AI추천